Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients
- PMID: 26296871
- DOI: 10.1136/jnnp-2015-311387
Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients
Abstract
Objectives: Biomarkers for the diagnosis of motoneuron diseases (MND) are urgently needed to improve the diagnostic pathway, patient stratification and monitoring. The aim of this study was to validate candidate markers for MND in cerebrospinal fluid (CSF) and specify cut-offs based on large patient cohorts by especially considering patients who were seen under the initial differential diagnosis (MND mimics).
Methods: In a prospective study, we investigated CSF of 455 patients for neurofilament light chain (NfL), phosphorylated heavy chain (pNfH), tau protein (Tau) and phospho-tau protein (pTau). Analysed cohorts included patients with apparently sporadic and familial amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS) (MND, n=253), MND mimics (n=85) and neurological control groups. Cut-off values were specified, and diagnostic performance and correlation with progression were analysed.
Results: Nfs were significantly higher in the MND group compared to the control groups, whereas Tau and pTau did not differ. At a cut-off level of 2200 pg/mL for NfL, a 77% diagnostic sensitivity (CI 71% to 82%), 85% specificity (CI 79% to 90%) and 87% positive predictive value (PPV) (CI 81% to 91%) were achieved. For pNfH, we calculated 83% sensitivity (CI 78% to 88%), 77% specificity (CI 71% to 83%) and 82% PPV (CI 77% to 86%) at 560 pg/mL. There were no significant differences between sporadic and genetic ALS or PLS. Nf levels were elevated at early disease stage, and correlated moderately with MND progression and duration.
Conclusions: Neurofilaments in CSF have a high relevance for the differential diagnosis of MNDs and should be included in the diagnostic work-up of patients. Their value as prognostic markers should be investigated further.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Comment in
-
Are neurofilaments heading for the ALS clinic?J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):3-4. doi: 10.1136/jnnp-2015-311934. Epub 2015 Oct 5. J Neurol Neurosurg Psychiatry. 2016. PMID: 26438577 No abstract available.
Similar articles
-
Diagnostic and prognostic value of CSF neurofilaments in a cohort of patients with motor neuron disease: A cross-sectional study.J Cell Mol Med. 2021 Apr;25(8):3765-3771. doi: 10.1111/jcmm.16240. Epub 2021 Feb 20. J Cell Mol Med. 2021. PMID: 33609080 Free PMC article.
-
Cerebrospinal Fluid Neurofilaments May Discriminate Upper Motor Neuron Syndromes: A Pilot Study.Neurodegener Dis. 2018;18(5-6):255-261. doi: 10.1159/000493986. Epub 2018 Nov 14. Neurodegener Dis. 2018. PMID: 30428468
-
Diagnostic value of neurofilaments in differentiating motor neuron disease from multifocal motor neuropathy.J Neurol. 2024 Jul;271(7):4441-4452. doi: 10.1007/s00415-024-12355-8. Epub 2024 Apr 29. J Neurol. 2024. PMID: 38683209 Free PMC article.
-
Diagnostic and Prognostic Role of Blood and Cerebrospinal Fluid and Blood Neurofilaments in Amyotrophic Lateral Sclerosis: A Review of the Literature.Int J Mol Sci. 2019 Aug 25;20(17):4152. doi: 10.3390/ijms20174152. Int J Mol Sci. 2019. PMID: 31450699 Free PMC article. Review.
-
CSF and blood levels of Neurofilaments, T-Tau, P-Tau, and Abeta-42 in amyotrophic lateral sclerosis: a systematic review and meta-analysis.J Transl Med. 2024 Oct 21;22(1):953. doi: 10.1186/s12967-024-05767-7. J Transl Med. 2024. PMID: 39434139 Free PMC article.
Cited by
-
Myelitis as a side effect of tofersen therapy in SOD1-associated ALS.J Neurol. 2024 Apr;271(4):2114-2118. doi: 10.1007/s00415-023-12130-1. Epub 2023 Dec 9. J Neurol. 2024. PMID: 38066205 Free PMC article. No abstract available.
-
Visinin-like protein 1 levels in blood and CSF as emerging markers for Alzheimer's and other neurodegenerative diseases.Alzheimers Res Ther. 2022 Nov 22;14(1):175. doi: 10.1186/s13195-022-01122-4. Alzheimers Res Ther. 2022. PMID: 36419075 Free PMC article.
-
Significance of CSF NfL and tau in ALS.J Neurol. 2018 Nov;265(11):2633-2645. doi: 10.1007/s00415-018-9043-0. Epub 2018 Sep 5. J Neurol. 2018. PMID: 30187162
-
Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS.Ann Clin Transl Neurol. 2019 Dec;6(12):2489-2502. doi: 10.1002/acn3.50943. Epub 2019 Nov 19. Ann Clin Transl Neurol. 2019. PMID: 31742901 Free PMC article.
-
CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration.Front Neurol. 2018 Dec 14;9:1037. doi: 10.3389/fneur.2018.01037. eCollection 2018. Front Neurol. 2018. PMID: 30631300 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous